Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)
NCT06636786
This study is recruiting at 8 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will examine the safety and efficacy of TNX-102 SL to reduce ASR symptoms and behavioral changes among patients presenting to the emergency department (ED) after motor vehicle collision (MVC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Acute Stress Reaction
- Acute Stress Disorder
- Neurocognitive Function
- Post-traumatic Stress
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of North Carolina, Chapel Hill
- Last updated on ClinicalTrials.gov
- September 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Indiana · 1
- Indiana University · Indianapolis, IN
Kansas · 1
- University of Kansas Medical Center · Kansas City, KS
Missouri · 1
- Washington University in St. Louis · St Louis, MO
New Jersey · 1
- Cooper University Health System · Camden, NJ
Ohio · 1
- The Ohio State University · Columbus, OH
Rhode Island · 2
- Rhode Island Hospital · Providence, RI
- The Miriam Hospital · Providence, RI
Texas · 1
- University of Texas Health Science Center at San Antonio · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.